Monoclate P (Antihemophilic factor [human] factor VIII) for Hemophilia

Overview Monoclate P is approved by the Food and Drug Administration (FDA) to control bleeding episodes and for perioperative (before, during, and after surgery) care in adults and children with factor VIII deficiency due to hemophilia A. The technical name of Monoclate P is Antihemophilic factor [human] factor VIII:C pasteurized monoclonal antibody purified. Monoclate P is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia. How do I take it? Prescribing information states that Monoclate P is given as an intravenous injection. Monoclate P comes in single-use vials and must be reconstituted before injection. Side effects The FDA-approved label for Monoclate P lists common side effects including mild chills, nausea, allergic reactions, and stinging at the injection site. Serious side effects listed for Monoclate P include hypersensitivity reactions and the development of inhibitors. For more details about this treatment, visit: Monoclate P - CSL Behring http://labeling.cslbehring.com/PI/US/Monoclate-P/EN/Monoclate-P-Prescribing-Information.pdf Treatment of Hemophilia - Hemophilia Federation of America http://www.hemophiliafed.org/bleeding-disorders/hemophilia/treatment/